Touchlight has secured £42m ($60m) in funding to support efforts to triple its manufacturing capacity of synthetic DNA based on the company’s proprietary dbDNA platform – an enzyme made minimal linear DNA vector. The completed facility will have the capacity to produce 1kg of GMP DNA per month, enough for one billion COVID-19 vaccine doses.
The Hampton, UK-based company has followed an unusual funding model to date. The latest financing of £42m was led by Bridford Investments and focused on “a network of ultra-high net worth individuals, family offices and specialist health care investors.”
Karen Fallen, CEO of Touchlight DNA Services, explained this was how the biotech had been financed from the beginning, following...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
